We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-0.27%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.53B
AUM Growth
+$1.73M
(+0.11%)
Cap. Flow
-$160M
Cap. Flow
% of AUM
-10.45%
Top 10 Holdings %
Top 10 Hldgs %
69.53%
Holding
250
New
32
Increased
47
Reduced
70
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
|
+$13.5M |
| 2 |
ARAV
Aravive, Inc. Common Stock
ARAV
|
+$11.9M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$4.02M |
| 4 |
AIXC
AIxCrypto Holdings Inc
AIXC
|
+$2.59M |
| 5 |
HURA
TuHURA Biosciences
HURA
|
+$2.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$59.2M |
| 2 |
United Therapeutics
UTHR
|
+$6.78M |
| 3 |
TSRO
TESARO, Inc.
TSRO
|
+$5.95M |
| 4 |
KITE
Kite Pharma, Inc.
KITE
|
+$4.37M |
| 5 |
SPNC
Spectranetics Corp
SPNC
|
+$3.48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 7.34% |
| 2 | Technology | 0.16% |
| 3 | Materials | 0.11% |
| 4 | Consumer Staples | 0.04% |
| 5 | Consumer Discretionary | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Merck
MRK
$326B
| $283M | 18.47% |
46,258
+3,438
| +8% | +$208K |
|
|
2
PUT
Bristol-Myers Squibb
BMY
$130B
| $211M | 13.77% |
33,069
-227
| -0.7% | -$13.3K |
|
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $126M | 8.21% |
5,000
+1,699
| +51% | +$419K |
|
4
CALL
AbbVie
ABBV
$465B
| $94.9M | 6.2% |
10,675
-601
| -5% | -$45.8K |
|
5
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $88.6M | 5.79% |
5,980
+1,922
| +47% | +$210K |
|
|
6
Bristol-Myers Squibb
BMY
$130B
| $62.7M | 4.09% |
982,955
-1,013,025
| -51% | -$59.2M |
|
7
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
| $55M | 3.59% |
4,680
+2,966
| +173% | +$253K |
|
|
BLUE
8
CALL
DELISTED
bluebird bio
BLUE
| $54M | 3.53% |
303
+111
| +58% | +$155K |
|
|
DBVT
9
CALL
DBV Technologies
DBVT
$799M
| $46.3M | 3.03% |
+1,091
| New | +$468K |
|
10
CALL
Vertex Pharmaceuticals
VRTX
$124B
| $43.6M | 2.85% |
2,865
-1,688
| -37% | -$254K |
|
|
11
PUT
Alnylam Pharmaceuticals
ALNY
$38.5B
| $37.2M | 2.43% |
3,165
+774
| +32% | +$66.1K |
|
12
CALL
Sarepta Therapeutics
SRPT
$1.63B
| $32.9M | 2.15% |
7,263
+1,617
| +29% | +$64.6K |
|
|
13
CALL
Bristol-Myers Squibb
BMY
$130B
| $27M | 1.76% |
4,230
-621
| -13% | -$36.3K |
|
|
14
PUT
Merck
MRK
$326B
| $26.8M | 1.75% |
4,380
-2,988
| -41% | -$181K |
|
15
CALL
Halozyme
HALO
$9.9B
| $22.6M | 1.48% |
13,037
+6,170
| +90% | +$83.6K |
|
|
16
PUT
Vertex Pharmaceuticals
VRTX
$124B
| $19.1M | 1.25% |
1,257
+446
| +55% | +$67.1K |
|
|
ZGNX
17
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $17.1M | 1.11% |
4,865
+3,130
| +180% | +$42.5K |
|
18
CALL
AstraZeneca
AZN
$267B
| $15.2M | 0.99% |
2,245
-9,966
| -82% | -$630K |
|
19
CALL
Cigna
CI
$79.6B
| $12.5M | 0.82% |
670
-1,858
| -73% | -$331K |
|
|
GWPH
20
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $11.7M | 0.76% |
1,149
+686
| +148% | +$73.5K |
|
|
KITE
21
PUT
DELISTED
Kite Pharma, Inc.
KITE
| $9.76M | 0.64% |
543
-248
| -31% | -$34.6K |
|
|
SGEN
22
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
| $9.44M | 0.62% |
1,734
+292
| +20% | +$14.9K |
|
|
CLVS
23
CALL
DELISTED
Clovis Oncology, Inc.
CLVS
| $9.16M | 0.6% |
1,112
-1,727
| -61% | -$137K |
|
24
PUT
Ionis Pharmaceuticals
IONS
$9.14B
| $8.17M | 0.53% |
1,612
+353
| +28% | +$18.5K |
|
|
BLUE
25
PUT
DELISTED
bluebird bio
BLUE
| $7.76M | 0.51% |
44
+7
| +19% | +$9.78K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q3 2017 Portfolio in Review
As of Q3 2017, Sabby Management held 250 positions worth $1.53B, up 0.11% from $1.53B the previous quarter. Its ten largest holdings account for 70% of the portfolio.
Sabby Management withdrew a net $160M in Q3 2017, closing 82 positions and reducing 70 holdings. Its most notable exit was United Therapeutics, an estimated $6.78M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 7.3% of assets, down from 13% a quarter earlier, followed by Technology and Materials.
Against the trend, Sabby Management opened a new position in Sio Gene Therapies Inc. Common Stock worth $4.42M.
- Sabby Management's largest Q3 2017 buy was Sio Gene Therapies Inc. Common Stock: 80,320 shares worth $4.42M.
- Sabby Management added most to TuHURA Biosciences in Q3 2017, an estimated $2.3M increase.
- Sabby Management's biggest Q3 2017 reduction was Bristol-Myers Squibb, cutting an estimated $59.2M.
- Sabby Management fully exited United Therapeutics in Q3 2017, selling an estimated $6.78M.
- Sabby Management's ten largest holdings make up 70% of its $1.53B portfolio in Q3 2017.
- Sabby Management opened 32 new positions and closed 82 in Q3 2017.
- Sabby Management's portfolio value rose 0.11% quarter-over-quarter to $1.53B.
Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.